Skip to main content
HBIO
NASDAQ Life Sciences

哈佛生物科学宣布1比10的反向股票拆分，于3月16日生效

feedReported by Dow Jones Newswires
Sentiment info
Negative
Importance info
8
Price
$0.495
Mkt Cap
$24.596M
52W Low
$0.281
52W High
$0.946
Market data snapshot near publication time

summarizeSummary

哈佛生物科学宣布了一比十的反向股票拆分，预计股票将于3月16日开始以拆分后的价格交易。这一企业行动通常由低股价的公司采取，旨在提高每股价格，通常是为了满足交易所上市的最低竞价要求。虽然反向拆分不会改变公司的总体市值或根本价值，但通常被市场视为负面信号，因为它可能表明潜在的财务困难或缺乏投资者信心。最近的8-K文件进一步确认，股东们已经批准了这一反向拆分，董事会现在已经最终确定，这凸显了这一决定对公司股权结构的立即影响。

在该公告发布时，HBIO的交易价格为$0.49，交易所为NASDAQ，所属行业为Life Sciences，市值约为$2459.6万。 52周交易区间为$0.28至$0.95。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed HBIO - Latest Insights

HBIO
Apr 21, 2026, 4:58 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Stockholders to Vote on Authorizing 520,000 New Shares for Employee Incentive Plans
Sentiment: Neutral
View Wiseek Article
HBIO
Apr 21, 2026, 4:56 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Shareholders to Vote on Significant Equity Plan Share Increases
Sentiment: Neutral
View Wiseek Article
HBIO
Apr 01, 2026, 9:44 AM EDT
Filing Type: 4
Importance Score:
7
CFO Mark Frost Buys $25,000 in Harvard Bioscience Stock Amidst Recent Insider Accumulation
Sentiment: Positive
View Wiseek Article
HBIO
Mar 23, 2026, 8:00 AM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
BroadOak Funds and Director Snider Disclose 15.97% Stake via Convertible Debt and Warrants, Securing Company Financing
Sentiment: Neutral
View Wiseek Article
HBIO
Mar 18, 2026, 2:13 PM EDT
Filing Type: 4
Importance Score:
8
Director Stephen Denelsky Buys $48.7K in Stock, Joining Recent Insider Accumulation
Sentiment: Positive
View Wiseek Article
HBIO
Mar 18, 2026, 7:31 AM EDT
Filing Type: 4
Importance Score:
7
Director William Snider Buys Over $103K in Harvard Bioscience Stock Post-Reverse Split
Sentiment: Positive
View Wiseek Article
HBIO
Mar 17, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Harvard Bioscience Issues FY26 Guidance Projecting Revenue and EBITDA Growth
Sentiment: Positive
View Wiseek Article
HBIO
Mar 13, 2026, 8:20 AM EDT
Filing Type: 10-K
Importance Score:
9
Harvard Bioscience Reports Significant FY2025 Loss, Refinances Debt, and Enacts Reverse Stock Split to Maintain Nasdaq Listing
Sentiment: Negative
View Wiseek Article
HBIO
Mar 12, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Harvard Bioscience Reports Significant FY25 Net Loss Driven by Goodwill Impairment; Provides 2026 Guidance
Sentiment: Negative
View Wiseek Article
HBIO
Mar 12, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Harvard Bioscience Reports $56.7M FY25 Net Loss Driven by Goodwill Impairment; Revenue Declines
Sentiment: Negative
View Wiseek Article